BioMimetic Dental Growth Factor Therapy PMA Set For FDA Panel Check-Up
This article was originally published in The Gray Sheet
Executive Summary
A PMA for BioMimetic Pharmaceuticals' GEM 21S synthetic bone-growth factor to treat osseous periodontal defects will be reviewed by FDA's Dental Products Panel July 13